Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pharmacotherapy

ACCORD Blood Pressure and ACCORD Lipid: how low can we go?

Nature Reviews Endocrinology volume 6, pages 483–484 (2010)Cite this article

Subjects

Lowering blood pressure to normal levels, below those currently recommended, does not reduce the risk of cardiovascular disease events in patients with type 2 diabetes mellitus. Nor does treating dyslipidemia with fibrate and statin combination therapy reduce the risk of cardiovascular disease events more than treatment with statin alone.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).

  2. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).

  3. [No authors listed] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981–2997 (2002).

  4. Hansson, L. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755–1762 (1998).

    Article  CAS  Google Scholar 

  5. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 370, 829–840 (2007).

    Article  CAS  Google Scholar 

  6. The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477–1490 (2010).

  7. Cooper-Dehoff, R. M. The INVEST trial. Presented at the American College of Cardiology Congress (2010).

  8. Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849–1861 (2005).

    Article  CAS  Google Scholar 

  9. Mannien, V. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85, 37–45 (1992).

    Article  Google Scholar 

  10. [No authors listed] Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102, 21–27 (2000).

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Bronx Lebanon Hospital, 1650 Grand Concourse, Bronx, 10457, NY, USA

    Mariela Glandt

  2. Diabetes Unit, Hadassah University Hospital, PO Box 12000, Jerusalem, 91120, Israel

    Itamar Raz

Authors
  1. Mariela Glandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Itamar Raz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Itamar Raz.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glandt, M., Raz, I. ACCORD Blood Pressure and ACCORD Lipid: how low can we go?. Nat Rev Endocrinol 6, 483–484 (2010). https://doi.org/10.1038/nrendo.2010.128

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2010.128

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing